Multi-omics profiling of retinal pigment epithelium reveals enhancer-driven activation of RANK-NFATc1 signaling in traumatic proliferative vitreoretinopathy

share:

Brief intro:

  • Author: Mengyu Liao, Xu Zhu, Yumei Lu, Xiaoping Yi, Youhui Hu, Yumeng Zhao, Zhisheng Ye, Xu Guo, Minghui Liang, Xin Jin, Hong Zhang, Xiaohong Wang, Ziming Zhao, Yupeng Chen & Hua Yan
  • Journal: Nature Communications
  • Doi: https://www.doi.org/10.1038/s41467-024-51624-y
  • Publication Date: 2024 Aug 25

Products/Services used in the paper

Quotation shows PackGene:For the gene therapy procedure, rAAV2/2 vectors, rAAV2/2-shNfatc1-Mus-1 (GCCGCAGAACACTACAGTT, AACTGTAGTGTTCTGCGGC) and rAAV2/2-shNfatc1-Mus-2 (GCTCAGAAACTCTGATAT, AATATCAGAGTTTCTGAGC) were obtained from PackGene Biotech and were delivered via a subretinal injection containing 4.9 × 109 viral genome copies in 1 μL volume.

Research Field:vitreoretinopathy

AAV Serotype:AAV2

Targeted organ:eye

Animal or cell line strain:mice

Request Quote

Abstract

During the progression of proliferative vitreoretinopathy (PVR) following ocular trauma, previously quiescent retinal pigment epithelial (RPE) cells transition into a state of rapid proliferation, migration, and secretion. The elusive molecular mechanisms behind these changes have hindered the development of effective pharmacological treatments, presenting a pressing clinical challenge. In this study, by monitoring the dynamic changes in chromatin accessibility and various histone modifications, we chart the comprehensive epigenetic landscape of RPE cells in male mice subjected to traumatic PVR. Coupled with transcriptomic analysis, we reveal a robust correlation between enhancer activation and the upregulation of the PVR-associated gene programs. Furthermore, by constructing transcription factor regulatory networks, we identify the aberrant activation of enhancer-driven RANK-NFATc1 pathway as PVR advanced. Importantly, we demonstrate that intraocular interventions, including nanomedicines inhibiting enhancer activity, gene therapies targeting NFATc1 and antibody therapeutics against RANK pathway, effectively mitigate PVR progression. Together, our findings elucidate the epigenetic basis underlying the activation of PVR-associated genes during RPE cell fate transitions and offer promising therapeutic avenues targeting epigenetic modulation and the RANK-NFATc1 axis for PVR management.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download